Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PRLD
stocks logo

PRLD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-0.180
-51.35%
20.50M
+412.5%
-0.280
-33.33%
--
--
-0.285
-30.49%
Estimates Revision
The market is revising No Change the revenue expectations for Prelude Therapeutics Incorporated (PRLD) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 25.20%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.3%
In Past 3 Month
Stock Price
Go Up
up Image
+25.20%
In Past 3 Month
Wall Street analysts forecast PRLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRLD is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast PRLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRLD is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.540
sliders
Low
5.00
Averages
5.00
High
5.00
Current: 1.540
sliders
Low
5.00
Averages
5.00
High
5.00
Citizens JMP
Outperform -> NULL
downgrade
$4 -> $3
2025-08-18
Reason
Citizens JMP
Price Target
$4 -> $3
2025-08-18
downgrade
Outperform -> NULL
Reason
Citizens JMP lowered the firm's price target on Prelude Therapeutics to $3 from $4 and keeps an Outperform rating on the shares. With initial PRT3789 monotherapy data validating the SMARCA2 target, the firm says PRT7732 has a path forward as a combination agent, the analyst tells investors in a research note.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$5
2025-04-08
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$5
2025-04-08
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Reni Benjamin
Buy
Reiterates
$4
2025-03-12
Reason
Citizens Capital Markets
Reni Benjamin
Price Target
$4
2025-03-12
Reiterates
Buy
Reason
JMP Securities
Reni Benjamin
Buy
Reiterates
$7 → $4
2024-12-11
Reason
JMP Securities
Reni Benjamin
Price Target
$7 → $4
2024-12-11
Reiterates
Buy
Reason
JMP Securities lowered the firm's price target on Prelude Therapeutics to $4 from $7 and keeps an Outperform rating on the shares after the company's ASH presentation, where it presented a poster highlighting PRT2527, a CDK9 inhibitor, as a monotherapy and in combination with Brukinsa. JMP continues to believe Prelude shares represent an attractive investment opportunity with three assets advancing through the clinic, initial PRT3789 monotherapy demonstrating modest efficacy and a potential path forward as a combination agent, and a cash position of $153.6M, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Prelude Therapeutics Inc (PRLD.O) is -1.50, compared to its 5-year average forward P/E of -5.08. For a more detailed relative valuation and DCF analysis to assess Prelude Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.08
Current PE
-1.50
Overvalued PE
2.63
Undervalued PE
-12.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.92
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.04
Undervalued EV/EBITDA
-9.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.09
Current PS
0.00
Overvalued PS
0.59
Undervalued PS
-0.41
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 188.46% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 188.46% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PRLD News & Events

Events Timeline

(ET)
2025-11-12
07:16:03
Prelude Therapeutics projects financial stability through 2027
select
2025-11-12
07:15:18
Prelude Therapeutics announces Q3 earnings per share of (26c), compared to (43c) in the previous year.
select
2025-11-04 (ET)
2025-11-04
07:35:01
Prelude Therapeutics Chief Medical Officer Jane Huang Leaves the Company
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-19Globenewswire
PRLD Investors Can Participate in Prelude Therapeutics Incorporated Fraud Investigation Led by Schall Law Firm

  • Investigation Announcement: The Schall Law Firm is investigating Prelude Therapeutics for potential violations of securities laws related to misleading statements and undisclosed information affecting investors.

  • Clinical Program Pause: Prelude Therapeutics announced a pause in its SMARCA2 degrader program on November 4, 2025, citing a review of clinical data and resource allocation decisions.

  • Stock Price Impact: Following the announcement of the program pause, Prelude's shares plummeted by nearly 55.8% on the same day.

  • Investor Support: The Schall Law Firm encourages affected shareholders to contact them for a free discussion about their rights and potential participation in the investigation.

[object Object]
Preview
9.0
11-19Globenewswire
Targeted Cancer Treatments Accelerate as Precision Medicine Market Exceeds $106 Billion

  • Precision Oncology Market Growth: The precision oncology sector is rapidly evolving, with the market reaching $106.21 billion in 2025 and projected to grow to $158.9 billion by 2029, driven by advancements in biomarker-driven therapies and immunotherapy modalities.

  • Oncolytics Biotech's Pivotal Trial: Oncolytics Biotech has received FDA alignment for its Phase 3 study of pelareorep in pancreatic cancer, aiming to provide the first immunotherapy option for this indication, with promising preliminary data showing significant response rates.

  • ALX Oncology's Clinical Success: ALX Oncology reported a 65% objective response rate for its candidate evorpacept in treating high CD47-expressing HER2-positive gastric cancer, significantly outperforming standard therapies and guiding future clinical strategies.

  • Innovations from Other Biotech Firms: Companies like Erasca, Immuneering, and Prelude Therapeutics are advancing their respective therapies and programs, with notable achievements in patent protections and promising clinical trial results, indicating a strong pipeline in the oncology sector.

[object Object]
Preview
9.5
11-12NASDAQ.COM
Prelude Therapeutics Inc Reports Smaller Q3 Loss, Surpassing Expectations

  • Earnings Performance: Prelude Therapeutics Inc reported a third-quarter loss of -$19.73 million, an improvement from -$32.27 million in the same period last year, and beat analysts' expectations of -$0.35 per share.

  • Revenue Growth: The company's revenue increased significantly by 116.7%, reaching $6.50 million compared to $3.00 million in the previous year.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Prelude Therapeutics Inc (PRLD) stock price today?

The current price of PRLD is 1.54 USD — it has increased 11.59 % in the last trading day.

arrow icon

What is Prelude Therapeutics Inc (PRLD)'s business?

Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.

arrow icon

What is the price predicton of PRLD Stock?

Wall Street analysts forecast PRLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRLD is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Prelude Therapeutics Inc (PRLD)'s revenue for the last quarter?

Prelude Therapeutics Inc revenue for the last quarter amounts to 6.50M USD, increased 116.67 % YoY.

arrow icon

What is Prelude Therapeutics Inc (PRLD)'s earnings per share (EPS) for the last quarter?

Prelude Therapeutics Inc. EPS for the last quarter amounts to -0.26 USD, decreased -39.53 % YoY.

arrow icon

What changes have occurred in the market's expectations for Prelude Therapeutics Inc (PRLD)'s fundamentals?

The market is revising No Change the revenue expectations for Prelude Therapeutics Incorporated (PRLD) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 25.20%.
arrow icon

How many employees does Prelude Therapeutics Inc (PRLD). have?

Prelude Therapeutics Inc (PRLD) has 131 emplpoyees as of December 05 2025.

arrow icon

What is Prelude Therapeutics Inc (PRLD) market cap?

Today PRLD has the market capitalization of 96.50M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free